{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:21:42Z","timestamp":1769030502737,"version":"3.49.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100018541","name":"Science Fund for Distinguished Young Scholars of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20200005"],"award-info":[{"award-number":["BK20200005"]}],"id":[{"id":"10.13039\/501100018541","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.xphs.2025.103707","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T18:56:13Z","timestamp":1740423373000},"page":"103707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric off-label use and nonadherence management for nadolol: A mechanistic PBPK model incorporating ontogeny scaling from interracial adults to children"],"prefix":"10.1016","volume":"114","author":[{"given":"Xiang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangji","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4628-9941","authenticated-orcid":false,"given":"Guo-Fu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2025.103707_bib0001","unstructured":"Food and Drug Administration. Corgard\u00ae tablets nadolol tablets USP. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/018063s065lbl.pdf. Accessed 11 Jan 2024."},{"key":"10.1016\/j.xphs.2025.103707_bib0002","unstructured":"Chinese National Healthcare Authorities. A top priority list of drug development for pediatric use. Available at: http:\/\/www.nhc.gov.cn\/yaozs\/s3581\/202305\/98c91d893dd740c3a03471f2fa1e65ba.shtml. Accessed 11 Aug 2023."},{"issue":"5","key":"10.1016\/j.xphs.2025.103707_bib0003","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/europace\/euaa376","article-title":"Life-threatening arrhythmias with autosomal recessive TECRL variants","volume":"23","author":"Webster","year":"2021","journal-title":"Europace"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0004","first-page":"165","article-title":"Analyses of triggers for recurrent cardiac events in 38 patients with symptomatic long QT syndrome]","volume":"49","author":"Li","year":"2021","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"5","key":"10.1016\/j.xphs.2025.103707_bib0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1161\/CIRCULATIONAHA.121.056018","article-title":"An international multicenter cohort study on \u03b2-blockers for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia","volume":"145","author":"Peltenburg","year":"2022","journal-title":"Circulation"},{"issue":"40","key":"10.1016\/j.xphs.2025.103707_bib0006","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","article-title":"2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"43","author":"Zeppenfeld","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.xphs.2025.103707_bib0007","doi-asserted-by":"crossref","DOI":"10.1093\/europace\/euad091","article-title":"Spotlight on the 2022 ESC guideline management of ventricular arrhythmias and prevention of sudden cardiac death: 10 novel key aspects","volume":"25","author":"K\u00f6nemann","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.xphs.2025.103707_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-021-02076-w","article-title":"Physiologically based pharmacokinetic models are effective support for pediatric drug development","volume":"22","author":"Wang","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ph17020265","article-title":"A comprehensive physiologically based pharmacokinetic model of nadolol in adults with renal disease and pediatrics with supraventricular tachycardia","volume":"17","author":"Kalsoom","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.xphs.2025.103707_bib0013","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/jcph.95","article-title":"Pharmacokinetic and pharmacodynamic interaction of nadolol with itraconazole, rifampicin and grapefruit juice in healthy volunteers","volume":"53","author":"Misaka","year":"2013","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2025.103707_bib0011","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00228-018-2436-2","article-title":"Role of (-)-epigallocatechin gallate in the pharmacokinetic interaction between nadolol and green tea in healthy volunteers","volume":"74","author":"Abe","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2025.103707_bib0012","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/clpt.2013.241","article-title":"Green tea ingestion greatly reduces plasma concentrations of nadolol in healthy subjects","volume":"95","author":"Misaka","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.xphs.2025.103707_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF00542499","article-title":"Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects","volume":"33","author":"Morrison","year":"1988","journal-title":"Eur J Clin Pharmacol"},{"issue":"5-6","key":"10.1016\/j.xphs.2025.103707_bib0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/j.1552-4604.1977.tb04609.x","article-title":"Metabolic studies in patients with nadolol: oral and intravenous administration","volume":"17","author":"Dreyfuss","year":"1977","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0016","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF00609676","article-title":"Separate and combined effects of nadolol and nifedipine on the cardiac response to exercise","volume":"28","author":"Wilkins","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.xphs.2025.103707_bib0017","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1023\/A:1015954108734","article-title":"Comparison of single-dose and steady-state nadolol plasma concentrations","volume":"7","author":"Krukemyer","year":"1990","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.xphs.2025.103707_bib0018","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/bdd.2510030107","article-title":"The effect of hydralazine on the pharmacokinetics of three different beta adrenoceptor antagonists: metoprolol, nadolol, and acebutolol","volume":"3","author":"Jack","year":"1982","journal-title":"Biopharm Drug Dispos"},{"issue":"4 Pt 2","key":"10.1016\/j.xphs.2025.103707_bib0019","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/0002-8703(84)90585-4","article-title":"Comparison of kinetic interactions of nadolol and propranolol with cimetidine","volume":"108","author":"Duchin","year":"1984","journal-title":"Am Heart J"},{"issue":"5","key":"10.1016\/j.xphs.2025.103707_bib0020","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/clpt.1983.79","article-title":"Enhancement of nadolol elimination by activated charcoal and antibiotics","volume":"33","author":"du Souich","year":"1983","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.xphs.2025.103707_bib0021","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF00546720","article-title":"Pharmacokinetics of nadolol in healthy subjects","volume":"26","author":"Sch\u00e4fer-Korting","year":"1984","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.xphs.2025.103707_bib0022","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1111\/bcp.14315","article-title":"Effects of single green tea ingestion on pharmacokinetics of nadolol in healthy volunteers","volume":"86","author":"Misaka","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2025.103707_bib0023","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/jcph.1812","article-title":"Urinary excretion of nadolol as a possible in vivo probe for drug interactions involving p-glycoprotein","volume":"61","author":"Shimazaki","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.xphs.2025.103707_bib0024","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/j.1552-4604.1992.tb03805.x","article-title":"Pharmacokinetics of nadolol in children with supraventricular tachycardia","volume":"32","author":"Mehta","year":"1992","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2025.103707_bib0025","doi-asserted-by":"crossref","first-page":"e00496","DOI":"10.1002\/prp2.496","article-title":"Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology","volume":"7","author":"\u00c5gesen","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.xphs.2025.103707_bib0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.009","article-title":"Erectile dysfunction and adherence to antihypertensive therapy: focus on \u03b2-blockers","volume":"81","author":"Manolis","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"4","key":"10.1016\/j.xphs.2025.103707_bib0027","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1021\/mp070028i","article-title":"Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership","volume":"4","author":"Yang","year":"2007","journal-title":"Mol Pharm"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0010","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.molpharmaceut.5b00733","article-title":"The nonmetabolized \u03b2-blocker nadolol is a substrate of OCT1, OCT2, MATE1, MATE2-K, and P-glycoprotein, but not of OATP1B1 and OATP1B3","volume":"13","author":"Misaka","year":"2016","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib0028","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s13318-016-0361-2","article-title":"Exploring the feasibility of biowaiver extension of BCS class III drugs with site-specific absorption using gastrointestinal simulation technology","volume":"42","author":"Sun","year":"2017","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"10.1016\/j.xphs.2025.103707_bib0029","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1056\/NEJM198109173051206","article-title":"Nadolol: a new beta-adrenoceptor antagonist","volume":"305","author":"Frishman","year":"1981","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.molpharmaceut.5b00733","article-title":"The nonmetabolized beta-blocker nadolol is a substrate of OCT1, OCT2, MATE1, MATE2-K, and P-glycoprotein, but not of OATP1B1 and OATP1B3","volume":"13","author":"Misaka","year":"2016","journal-title":"Mol Pharm"},{"issue":"21","key":"10.1016\/j.xphs.2025.103707_bib0031","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215303","article-title":"Protein abundance of clinically relevant drug transporters in the human kidneys","volume":"20","author":"Oswald","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.xphs.2025.103707_bib0032","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1124\/dmd.116.072066","article-title":"Abundance of drug transporters in the human kidney cortex as quantified by quantitative targeted proteomics","volume":"44","author":"Prasad","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.xphs.2025.103707_bib0033","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/17425255.2017.1253679","article-title":"The role of organic anion transporting polypeptides in drug absorption, distribution, excretion and drug-drug interactions","volume":"13","author":"Kovacsics","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"10.1016\/j.xphs.2025.103707_bib0072","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/jcpt.13764","article-title":"Clinical pharmacokinetics of nadolol: a systematic review","volume":"47","author":"Kalsoom","year":"2022","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0073","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejpb.2011.04.010","article-title":"Effect of the non-ionic surfactant Poloxamer 188 on passive permeability of poorly soluble drugs across Caco-2 cell monolayers","volume":"79","author":"Fischer","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.xphs.2025.103707_bib0034","doi-asserted-by":"crossref","DOI":"10.1038\/s41573-023-00877-1","article-title":"Membrane transporters in drug development and as determinants of precision medicine","author":"Galetin","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"10.1016\/j.xphs.2025.103707_bib0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","article-title":"PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin","volume":"7","author":"Hanke","year":"2018","journal-title":"Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin. CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib0036","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/cpt.2636","article-title":"Renal transporter-mediated drug-biomarker interactions of the endogenous substrates creatinine and N1-methylnicotinamide: a PBPK modeling approach","volume":"112","author":"T\u00fcrk","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.xphs.2025.103707_bib75","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.xphs.2018.02.021","article-title":"Quantitative estimation of plasma free drug fraction in patients with varying degrees of hepatic impairment: a methodological evaluation","volume":"107","author":"Li","year":"2018","journal-title":"J Pharm Sci"},{"issue":"8","key":"10.1016\/j.xphs.2025.103707_bib0037","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1016\/j.xphs.2019.03.002","article-title":"Successful prediction of human pharmacokinetics by improving calculation processes of physiologically based pharmacokinetic approach","volume":"108","author":"Mayumi","year":"2019","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2025.103707_bib0038","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40262-022-01181-8","article-title":"Feasibility of a pragmatic PBPK modeling approach: towards model-informed dosing in pediatric clinical care","volume":"61","author":"van der Heijden","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.xphs.2025.103707_bib0039","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1124\/dmd.122.001129","article-title":"Predictive performance of physiologically based pharmacokinetic modelling of beta-lactam antibiotic concentrations in adipose, bone, and muscle tissues","volume":"51","author":"De Sutter","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0040","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1124\/dmd.110.036103","article-title":"Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions","volume":"39","author":"Guest","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.xphs.2025.103707_bib0041","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.xphs.2024.02.024","article-title":"Facing the facts of altered plasma protein binding: do current models correctly predict changes in fraction unbound in special populations?","volume":"113","author":"Al-Qassabi","year":"2024","journal-title":"J Pharm Sci"},{"issue":"11","key":"10.1016\/j.xphs.2025.103707_bib0042","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.xphs.2024.08.020","article-title":"Predicting plasma protein binding of drugs in special populations: are all models wrong, but can some be recalibrated, refined, and become more useful?","volume":"113","author":"Li","year":"2024","journal-title":"J Pharm Sci"},{"issue":"6","key":"10.1016\/j.xphs.2025.103707_bib0043","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1208\/s12248-014-9652-1","article-title":"Similarities and differences in gastrointestinal physiology between neonates and adults: a physiologically based pharmacokinetic modeling perspective","volume":"16","author":"Yu","year":"2014","journal-title":"AAPS J"},{"issue":"7","key":"10.1016\/j.xphs.2025.103707_bib0044","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1124\/dmd.115.068700","article-title":"Examining small intestinal transit time as a function of age: is there evidence to support age-dependent differences among children?","volume":"44","author":"Maharaj","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.xphs.2025.103707_bib0045","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s11095-019-2708-2","article-title":"Physiologically based pharmacokinetic modeling of oxycodone in children to support pediatric dosing optimization","volume":"36","author":"Zheng","year":"2019","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0046","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1208\/s12248-013-9451-0","article-title":"A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam","volume":"15","author":"Maharaj","year":"2013","journal-title":"AAPS J"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0047","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/17425255.2021.2027907","article-title":"An update on the use of allometric and other scaling methods to scale drug clearance in children: towards decision tables","volume":"18","author":"van Rongen","year":"2022","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"1","key":"10.1016\/j.xphs.2025.103707_bib0048","first-page":"S56","article-title":"Incorporating ontogeny in physiologically based pharmacokinetic modeling to improve pediatric drug development: what we know about developmental changes in membrane transporters","volume":"59","author":"Cheung","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib0049","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cpt.176","article-title":"Human ontogeny of drug transporters: review and recommendations of the pediatric transporter working group","volume":"98","author":"Brouwer","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2025.103707_bib0050","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1208\/s12248-019-0359-1","article-title":"Optimized renal transporter quantification by using aquaporin 1 and aquaporin 2 as anatomical markers: application in characterizing the ontogeny of renal transporters and its correlation with hepatic transporters in paired human samples","volume":"21","author":"Li","year":"2019","journal-title":"AAPS J"},{"issue":"7","key":"10.1016\/j.xphs.2025.103707_bib0051","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40262-019-00737-5","article-title":"Impact of ethnicity-specific hepatic microsomal scaling factor, liver weight, and cytochrome P450 (CYP) 1A2 content on physiologically based prediction of CYP1A2-mediated pharmacokinetics in young and elderly Chinese adults","volume":"58","author":"Li","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.xphs.2025.103707_bib0052","first-page":"279","article-title":"A comparison of alpha 1-acid glycoprotein (AAG) concentration and disopyramide binding in Chinese and Japanese]","volume":"74","author":"Jin","year":"1999","journal-title":"Hokkaido Igaku Zasshi"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0053","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40262-013-0119-9","article-title":"Ethnic-specific in vitro-in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in the Chinese population: opportunities and challenges","volume":"53","author":"Li","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"12","key":"10.1016\/j.xphs.2025.103707_bib0054","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40262-013-0089-y","article-title":"Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling","volume":"52","author":"Barter","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"10.1016\/j.xphs.2025.103707_bib0055","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00228-018-02610-z","article-title":"Interethnic scaling of fraction unbound of a drug in plasma and volume of distribution: an analysis of extrapolation from Caucasians to Chinese","volume":"75","author":"Yu","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.xphs.2025.103707_bib0056","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1542\/peds.2012-0055I","article-title":"Standard 6: age groups for pediatric trials","author":"Williams","year":"2012","journal-title":"Pediatrics"},{"key":"10.1016\/j.xphs.2025.103707_bib0057","unstructured":"European Medicines Agency. ICH Topic E 11 clinical investigation of medicinal products in the paediatric population. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/e-11-clinical-investigation-medicinal-products-paediatric-population-step-5_en.pdf. Accessed 11 Sep 2023."},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0058","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40262-021-01072-4","article-title":"Development and evaluation of a virtual population of children with obesity for physiologically based pharmacokinetic modeling","volume":"61","author":"Gerhart","year":"2022","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"10.1016\/j.xphs.2025.103707_bib0059","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.clinthera.2021.08.006","article-title":"Pooled analysis of gastric emptying in patients with obesity: implications for oral absorption projection","volume":"43","author":"Lu","year":"2021","journal-title":"Clin Ther"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib0060","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13318-019-00598-0","article-title":"How to handle delayed or missed doses: a population pharmacokinetic perspective","volume":"45","author":"Gu","year":"2020","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib0061","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1460-9592.2010.03473.x","article-title":"Knowledge-driven approaches for the guidance of first-in-children dosing","volume":"21","author":"Edginton","year":"2011","journal-title":"Paediatr Anaesth"},{"issue":"2","key":"10.1016\/j.xphs.2025.103707_bib74","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13318-020-00667-9","article-title":"Abundance and associated variations of cytochrome P450 drug-metabolizing enzymes in the liver of East Asian adults: a meta-analysis","volume":"46","author":"An","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib0062","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/bdd.2052","article-title":"Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions","volume":"38","author":"Nicolas","year":"2017","journal-title":"Biopharm Drug Dispos"},{"issue":"12","key":"10.1016\/j.xphs.2025.103707_bib0063","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s40262-016-0422-3","article-title":"Development of a whole-body physiologically based pharmacokinetic approach to assess the pharmacokinetics of drugs in elderly individuals","volume":"55","author":"Schlender","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.xphs.2025.103707_bib0064","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/eurheartj\/ehs229","article-title":"Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy","volume":"35","author":"Miyamoto","year":"2014","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.xphs.2025.103707_bib0065","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1152\/japplphysiol.00627.2013","article-title":"\u03b2-Adrenergic receptor antagonism in mice: a model for pediatric heart disease","volume":"115","author":"Sucharov","year":"1985","journal-title":"J Appl Physiol"},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib0066","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/01.RES.59.3.297","article-title":"Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure","volume":"59","author":"Bristow","year":"1986","journal-title":"Circ Res"},{"key":"10.1016\/j.xphs.2025.103707_bib0067","unstructured":"Food and Drug Administration. Clinical pharmacology and biopharmaceutics reviews. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/205410Orig1s000ClinPharmR.pdf. Accessed 2024 Dec 29."},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib0068","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S0735-1097(10)80283-9","article-title":"Efficacy and safety of intravenous and oral nadolol for supraventricular tachycardia in children","volume":"19","author":"Mehta","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.xphs.2025.103707_bib0069","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jamapediatrics.2021.4565","article-title":"Noninferiority and safety of nadolol vs propranolol in infants with infantile hemangioma: a randomized clinical trial","volume":"176","author":"Pope","year":"2022","journal-title":"JAMA Pediatr"},{"issue":"11","key":"10.1016\/j.xphs.2025.103707_bib0070","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/jcph.744","article-title":"Exposure matching for extrapolation of efficacy in pediatric drug development","volume":"56","author":"Mulugeta","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2025.103707_bib0071","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1161\/CIRCRESAHA.118.313220","article-title":"Adherence in hypertension","volume":"124","author":"Burnier","year":"2019","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.xphs.2025.103707_bib76","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s13318-018-0494-6","article-title":"Model-informed approaches for alternative aripiprazole dosing regimens and missed dose management: towards better adherence to antipsychotic pharmacotherapy","volume":"43","author":"Wu","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib77","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s13318-017-0452-8","article-title":"Modeling drug disposition and drug-drug interactions through hypothesis-driven physiologically based pharmacokinetics: a reversal translation perspective","volume":"43","author":"Li","year":"2018","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.xphs.2025.103707_bib78","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.drudis.2019.01.003","article-title":"Gastric-acid-mediated drug-drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies","volume":"24","author":"Yu","year":"2019","journal-title":"Drug Discov Today"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354925001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T06:15:15Z","timestamp":1768976115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354925001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":78,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0022354925001431"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103707","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric off-label use and nonadherence management for nadolol: A mechanistic PBPK model incorporating ontogeny scaling from interracial adults to children","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2025.103707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Pharmacists Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103707"}}